CD4 and neoplasm: demonstrated that IL-6 blockade led to improved survival with an increased frequency of tumor-associated anti-CTLA4-induced CD8+ and CD4+ T effector cells and reduced Th17 CD4+ T cells, macrophages and myeloid cells (23).